5月7日,远大医药早盘高开10.68%,报6.63港元。其全资附属公司Grand Medical开发的创新药物STC3141在中国用于治疗脓毒症的II期临床研究成功达到临床终点,研发进度领先全球。此次进展标志着公司在危重症领域取得重要突破,受到市场关注。免责声明:本文内容由开放的智能模型自动生成,仅供参考。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.